Educational research on US and Indian equities, ETFs, mutual funds and crypto, with screeners and a free investing academy.
All data is for educational purposes only and should not be considered investment advice.
Equiscale is operated by Syntellia LLC, a Delaware limited liability company.
© 2026 Syntellia LLC. All rights reserved.
Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. It focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer. The company was incorporated in 2009 and is headquartered in Boston, Massachusetts.
Rule-based from financial data. Not advice.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 5 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $0M | $-112M | $-106M | $-85M | -77.6% | - | 22.2% |
| 2024 | $0M | $-95M | $-87M | $-81M | -57.2% | - | 13.8% |
| 2023 | $0M | $-84M | $-76M | $-65M | -33.8% | - | 30.0% |
| 2022 | $0M | $-59M | $-59M | $-56M | -30.0% | - | - |
| 2021 | - | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2025 |
|---|---|
| Total Revenue | 0 |
| Operating Revenue | 0 |
| Operating Expense | 112.79 |
| Research And Development | 90.30 |
| Selling General And Administration | 22.49 |
| Total Expenses | 112.79 |
| Operating Income | -112.79 |
| Total Operating Income As Reported | -112.79 |
| EBITDA | -111.66 |
| Normalized EBITDA | -111.66 |
| EBIT | -112.79 |
| Interest Income | 6.63 |
| Net Interest Income | 6.63 |
| Other Non Operating Income Expenses | 0.08 |
| Other Income Expense | 0.08 |
| Interest Income Non Operating | 6.63 |
| Net Non Operating Interest Income Expense | 6.63 |
| Pretax Income | -106.08 |
| Tax Provision | 0.11 |
| Tax Rate For Calcs | 0 |
| Tax Effect Of Unusual Items | 0 |
| Net Income Continuous Operations | -106.19 |
| Net Income From Continuing And Discontinued Operation | -106.19 |
| Net Income From Continuing Operation Net Minority Interest | -106.19 |
| Net Income | -106.19 |
| Net Income Common Stockholders | -106.19 |
| Net Income Including Noncontrolling Interests | -106.19 |
| Normalized Income | -106.19 |
| Diluted NI Availto Com Stockholders | -106.19 |
| Basic Average Shares | 60.34 |
| Diluted Average Shares | 60.34 |
| Reconciled Depreciation | 1.13 |
| Total Unusual Items | - |
| Total Unusual Items Excluding Goodwill | - |
| Preferred Stock Dividends | - |
| Special Income Charges | - |
| Gain On Sale Of Security | - |
| General And Administrative Expense | 22.49 |
| Other Gand A | 22.49 |
| Gain On Sale Of Ppe | - |
| Total Other Finance Cost | - |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Aura Biosciences, Inc.this co. | AURA | $703M | -6.62 | 5.13 | -77.6% | -5.92 |
| Bright Minds Biosciences Inc. | DRUG | $731M | -59.77 | 8.91 | -14.9% | -46.77 |
| Solid Biosciences Inc. | SLDB | $713M | -4.09 | 3.96 | -96.8% | -3.80 |
| CBLL | CBLL | $711M | -13.32 | 4.58 | -34.4% | -13.81 |
| Enhabit, Inc. | EHAB | $707M |
| - |
| - |
| - |
| - |
| -153.68 |
| 1.32 |
| -0.9% |
| 20.09 |
| Allogene Therapeutics, Inc. | ALLO | $704M | -3.69 | 2.41 | -65.3% | -4.15 |
| Candel Therapeutics, Inc. | CADL | $679M | -17.79 | 13.08 | -73.5% | -17.28 |
| Design Therapeutics, Inc. | DSGN | $672M | -9.63 | 3.16 | -32.8% | -8.33 |
| CorMedix Inc. | CRMD | $670M | 4.13 | 1.65 | 40.0% | 4.01 |
| Peer Median | - | -11.47 | 3.56 | -33.6% | -6.24 | |